{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:26:21Z","timestamp":1791163581717,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1067\/moe.2003.30","type":"journal-article","created":{"date-parts":[[2003,2,17]],"date-time":"2003-02-17T22:37:05Z","timestamp":1045521425000},"page":"38-44","source":"Crossref","is-referenced-by-count":49,"title":["A pilot study to test the efficacy of oral administration of interferon-\u03b1 lozenges to patients with Sj\u00f6gren's syndrome"],"prefix":"10.1067","volume":"95","author":[{"given":"Artur V.","family":"Khurshudian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/moe.2003.30_bib1","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/oxfordjournals.bmb.a072018","article-title":"Interferons and natural killer cells","volume":"41","author":"Rager-Zisman","year":"1985","journal-title":"Br Med Bull"},{"key":"10.1067\/moe.2003.30_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.7326\/0003-4819-96-1-80","article-title":"Interferon: immunobiology and clinical significance","volume":"96","author":"Stiehm","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1067\/moe.2003.30_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJM199701303360507","article-title":"Drug therapy: the treatment of chronic viral hepatitis","volume":"336","author":"Hoofnagle","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1067\/moe.2003.30_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2796.1992.tb00939.x","article-title":"AIDS-associated Kaposi's sarcoma and the mechanisms of interferon alpha's activity: a riddle within a puzzle","volume":"231","author":"de Witt","year":"1992","journal-title":"J Intern Med"},{"key":"10.1067\/moe.2003.30_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1365-2141.1999.01500.x","article-title":"Hairy-cell leukemia: biology and management","volume":"106","author":"Pettitt","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1067\/moe.2003.30_bib6","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/0002-9378(95)90404-2","article-title":"Management of condilomata acuminata with Alferon N injection, interferon alpha-n3 (human leukocyte derived)","volume":"172","author":"Friedman-Kien","year":"1995","journal-title":"Am J Obstet Gynecol"},{"key":"10.1067\/moe.2003.30_bib7","first-page":"846","article-title":"Interferon alpha therapy against metastatic iris tumor of renal cell carcinoma","volume":"118","author":"Ikeda","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1067\/moe.2003.30_bib8","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1365-2141.1998.01038.x","article-title":"Reactivation of Behcet's disease in the course of multicentric HHV8-positive Castleman's disease: long-term complete remission by a combined chemo\/radiation and interferon-alpha therapy regimen","volume":"103","author":"Strohal","year":"1998","journal-title":"Br J Haemotol"},{"key":"10.1067\/moe.2003.30_bib9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.5694\/j.1326-5377.1992.tb137004.x","article-title":"The clinical application of the interferons: a review","volume":"156","author":"Stuart-Harris","year":"1992","journal-title":"Med J Aust"},{"key":"10.1067\/moe.2003.30_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/29.1.50","article-title":"Immunoreactive circulating alpha-interferon is low in Sjogren's syndrome","volume":"29","author":"Shiozawa","year":"1990","journal-title":"Br J Rheum"},{"key":"10.1067\/moe.2003.30_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/jir.1998.18.255","article-title":"Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's Syndrome","volume":"18","author":"Shiozawa","year":"1998","journal-title":"J Interferon Cytokine Res"},{"key":"10.1067\/moe.2003.30_bib12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0738-081X(00)00135-8","article-title":"Sjogren's syndrome","volume":"18","author":"Fox","year":"2000","journal-title":"Clin Dermatol"},{"key":"10.1067\/moe.2003.30_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14219\/jada.archive.1993.0064","article-title":"Sjogren's syndrome: oral and dental considerations","volume":"124","author":"Atkinson","year":"1993","journal-title":"J Am Dent Assoc"},{"key":"10.1067\/moe.2003.30_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/0030-4220(86)90313-0","article-title":"Sjogren's syndrome: clinical and laboratory features, immunopathogenesis, and management","volume":"62","author":"Scully","year":"1986","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1067\/moe.2003.30_bib15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.7326\/0003-4819-92-2-212","article-title":"Sjogren's syndrome: current issues","volume":"92","author":"Moutspoulos","year":"1980","journal-title":"Ann Intern Med"},{"key":"10.1067\/moe.2003.30_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00002281-200009000-00007","article-title":"Update in Sjogren's syndrome","volume":"12","author":"Fox","year":"2000","journal-title":"Curr Opin Rheum"},{"key":"10.1067\/moe.2003.30_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0030-4220(81)90335-2","article-title":"The use of saliva substitutes as treatment for xerostomia in Sjogren's syndrome","volume":"52","author":"Weisz","year":"1981","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1067\/moe.2003.30_bib18","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","article-title":"Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren's syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial\u2014P92-01 Study Group","volume":"159","author":"Vivino","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1067\/moe.2003.30_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0030-4220(93)90092-I","article-title":"Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction","volume":"75","author":"Ferguson","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1067\/moe.2003.30_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1754-4505.1982.tb00027.x","article-title":"Clinical trials of a sialogogue in humans: a preliminary report","volume":"2","author":"Epstein","year":"1982","journal-title":"Spec Care Dent"},{"key":"10.1067\/moe.2003.30_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0030-4220(83)90096-8","article-title":"Effect of Sialor in treatment of xerostomia in Sjogren's syndrome","volume":"56","author":"Epstein","year":"1983","journal-title":"Oral Surg"},{"key":"10.1067\/moe.2003.30_bib22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/archopht.1996.01100140632033","article-title":"Systemic pilocarpine toxicity from Ocusert leakage","volume":"114","author":"Kushnick","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1067\/moe.2003.30_bib23","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1001\/jama.1994.03510460034022","article-title":"The aggravation of dementia by pilocarpine","volume":"271","author":"Fraunfelder","year":"1994","journal-title":"JAMA"},{"key":"10.1067\/moe.2003.30_bib24","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.1780360309","article-title":"Preliminary criteria for the classification of Sjogren's syndrome: results of an EEC prospective concerted action","volume":"36","author":"Vitali","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1067\/moe.2003.30_bib25","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.55.2.116","article-title":"Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of perspective multicentre study\u2014The European Study Group on Diagnostic Criteria for Sjogren's syndrome","volume":"55","author":"Vitali","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1067\/moe.2003.30_bib26","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1213\/00000539-199912000-00038","article-title":"The pain visual analog scale: is it linear or nonlinear?","volume":"89","author":"Myles","year":"1999","journal-title":"Anesth Analg"},{"key":"10.1067\/moe.2003.30_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/jcp.21.5.656","article-title":"Labial salivary gland biopsy in Sjogren's syndrome","volume":"21","author":"Chisholm","year":"1968","journal-title":"J Clin Pathol"},{"key":"10.1067\/moe.2003.30_NEWBIB1","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0002-9394(61)91827-X","article-title":"Standardized Schirmer tear test kit","volume":"51","author":"Halberg","year":"1961","journal-title":"Am J Ophthalmol"},{"key":"10.1067\/moe.2003.30_bib29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/107999099313497","article-title":"Treatment of primary Sjogren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial","volume":"19","author":"Ship","year":"1999","journal-title":"J interferon Cytokine Res"},{"key":"10.1067\/moe.2003.30_bib30","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/107999099313479","article-title":"Interferon-alpha upregulates gene expression of aquaporine-5 in human parotid glands","volume":"19","author":"Smith","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1067\/moe.2003.30_bib31","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1089\/107999099313505","article-title":"Oral administration of interferon-alpha induces a transient decline in oral mucosal immunoglobulins and an increase in interleukin-5","volume":"19","author":"Naylor","year":"1999","journal-title":"J Interferon Cytokine Res"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210402916318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079210402916318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T21:27:21Z","timestamp":1704749241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079210402916318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["S1079210402916318"],"URL":"https:\/\/doi.org\/10.1067\/moe.2003.30","relation":{},"ISSN":["1079-2104"],"issn-type":[{"value":"1079-2104","type":"print"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}